Lates News

According to a report released by Open Source Securities on August 20, each quick AI newsletter gives Jingrui Pharmaceuticals (600285.SH) a buy rating. The main reasons for this rating include: 1) Completion of external expansion mergers to promote the creation of a second growth curve; 2) Continuous strengthening of research and development innovation to enhance brand power. (Daily Economic News)